Why alcohol may hit harder for people on GLP-1 drugs like Ozempic, Wegovy

A Yale study suggests GLP-1 drugs like semaglutide slow alcohol breakdown in the liver, raising blood alcohol levels even as they reduce toxic byproducts linked to inflammation and liver damage

alcohol consumption
Yale study warns Ozempic users may get drunk faster with the same drinks. (Photo: AdobeStock)
Barkha Mathur New Delhi
4 min read Last Updated : Nov 19 2025 | 12:56 PM IST
People taking Ozempic, Wegovy, or other GLP-1 drugs may get drunk faster and stay intoxicated longer, according to new research from Yale School of Medicine.
 
The study, titled GLP-1 receptor agonism results in reduction in hepatic ethanol metabolism and published in npj Metabolic Health and Disease, shows that these medications slow the liver’s ability to break down alcohol. That means higher blood alcohol levels from the same amount of drinking, even as the drugs reduce toxic byproducts that harm the liver.
 
According to the Yale team, the study demonstrates that GLP-1 receptor agonists, including semaglutide, inhibit the activity of a key liver enzyme, Cyp2e1. This enzyme normally helps break down alcohol into acetaldehyde, a highly toxic compound responsible for liver inflammation and damage.
 
By suppressing Cyp2e1, GLP-1 drugs slow down the conversion of alcohol. This means:
  • Less acetaldehyde is produced.
  • The liver may experience less oxidative stress and inflammation.
  • Alcohol stays in the bloodstream for longer.
In mice, this shift resulted in noticeably higher blood alcohol concentrations (BAC) after the same amount of alcohol.
 
If these findings translate to humans, someone on a GLP-1 drug might:
  • Feel drunk faster
  • Stay impaired longer
  • Reach legal intoxication after fewer drinks
  • Underestimate their BAC
  • Experience stronger-than-expected cognitive effects

If GLP-1 drugs protect the liver, why is a higher BAC a concern?

The study authors say that while slowing alcohol breakdown protects the liver, it raises the amount of alcohol circulating in the bloodstream, and the rest of the body may feel a bigger hit.
 
Researchers say human trials are now needed to map this interaction more precisely. 

Could GLP-1 drugs help people with alcohol-related liver disease?

The new study shows a possibility as the liver receives less acetaldehyde exposure, even if a person continues to drink occasionally. So, GLP-1 drugs might:
  • Slow progression of alcohol-related liver disease (ALD)
  • Reduce inflammation
  • Lower oxidative injury
  • Improve steatosis
Several clinical trials are already testing semaglutide in patients with alcohol-related liver disease, and early signals look promising. 

Should people on GLP-1 drugs avoid alcohol altogether?

There is no rule against it yet, but this study suggests that caution is wise because of the faster and longer intoxication, and greater cognitive impairment risks.
 
For someone who drinks socially, this might mean the same drink now “hits harder”. For someone driving, the risks become more serious because even two drinks might push BAC above legal limits.
 
As the GLP-1 drugs use is increasing exponentially in India, thousands of people are unknowingly mixing alcohol with medications, making the findings of this study important for Indians who consume alcohol and are also on semaglutide. 

Since you're already here

…and clearly interested in your health, take a moment to explore our varied range of stories on wellness, medical research, and public health insights.

For more health updates, follow #HealthWithBS 
This content is for informational purposes only and is not a substitute for professional medical advice.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Health with BSBS Web Reportsweight losshealth newsalcoholObesity

First Published: Nov 19 2025 | 12:55 PM IST

Next Story